Logo image of IMRA

BITWISE MARA INCOME STRAT (IMRA) Stock Overview

USA - NYSEARCA:IMRA - US0917487078 - ETF

32.8513 USD
-0.02 (-0.06%)
Last: 10/29/2025, 8:04:01 PM
33.47 USD
+0.62 (+1.88%)
After Hours: 10/29/2025, 8:04:01 PM
Buy % Consensus

43

ChartMill assigns a Buy % Consensus number of 43% to IMRA. The Buy consensus is the weighted average rating of the current analysts ratings.

IMRA was analyzed by 6 analysts. The buy percentage consensus is at 43. So analysts seem to be rather negative about IMRA.
In the previous month the buy percentage consensus was at a similar level.
IMRA was analyzed by 6 analysts. More opinions would make the average more meaningful.

Related screens

IMRA Historical Analyst RatingsIMRA Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -33 -30 -27 -24 -21 -18 -15 -12 -9 -6 -3 0 2 4 6 8

Related screens

IMRA Current Analyst RatingIMRA Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 0.5 1 1.5 2 2.5
Up and Down Grades
Date Firm Action Rating
2022-01-06 Morgan Stanley Maintains Equal-Weight
2021-11-30 HC Wainwright & Co. Initiate Buy
2021-08-11 Morgan Stanley Downgrade Overweight -> Equal-Weight
2021-04-19 Morgan Stanley Maintains Overweight
2021-03-08 SVB Leerink Maintains Outperform
2021-03-08 Morgan Stanley Maintains Overweight

BITWISE MARA INCOME STRAT / IMRA FAQ

What does IMRA do?

Imara, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Brookline, Massachusetts and currently employs 6 full-time employees. The company went IPO on 2020-03-12. The firm is focused on developing and commercializing therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin and other serious diseases. Its lead product candidate, tovinontrine (IMR-687), is an oral, highly selective, potent small molecule inhibitor of phosphodiesterase-9 (PDE9). PDE9 selectively degrades cyclic guanosine monophosphate (cGMP), an active signaling molecule. IMR-687 is in Phase IIb clinical development for the treatment of sickle cell disease (SCD) and beta- thalassemia. The company is also focused on initiating a Phase II clinical trial of IMR-687 in heart failure with preserved ejection fraction (HFpEF). The firm is also focused on development of IMR-261, an oral, clinic-ready activator of nuclear factor erythroid 2-related factor 2 (Nrf2).


What is the stock price of BITWISE MARA INCOME STRAT today?

The current stock price of IMRA is 32.8513 USD. The price decreased by -0.06% in the last trading session.


How is the ChartMill rating for BITWISE MARA INCOME STRAT?

IMRA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.